Shionogi
Focus: Shionogi is a Japanese pharmaceutical company founded in 1878 with a focused portfolio in infectious diseases and small-molecule therapeutics. The company is heavily dependent on its lead asset FETROJA (cefiderocol), which represents 100% of current revenue.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Open Jobs
40+90 this month
Hot — 193 jobs added in 30d
Net +90 (193 new, 103 removed). Aggressive expansion phase.
Should You Work at Shionogi?
AI assessmentShionogi is a stable, niche infectious-disease player suitable for professionals seeking specialized expertise and job security through 2035, but with elevated portfolio risk and limited pipeline optionality.
Why Work Here
- Established 145-year-old Japanese company with deep R&D heritage and global reach in infectious disease, a high-value therapeutic area.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$4M Part DStable
Peak9.2yr
Sole revenue driver; peak sales expected over next decade before patent expiry.
Help build intelligence for Shionogi
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.